行情

AVEO

AVEO

AVEO制药
NASDAQ

实时行情|Nasdaq Last Sale

0.7127
-0.0421
-5.58%
已收盘, 18:55 12/09 EST
开盘
0.7500
昨收
0.7548
最高
0.7502
最低
0.6910
成交量
131.59万
成交额
--
52周最高
2.140
52周最低
0.4692
市值
1.15亿
市盈率(TTM)
2.720
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AVEO 新闻

  • Aveo down 7% premarket on "positive" late-stage tivozanib data in kidney cancer
  • Seeking Alpha - Article.5天前
  • AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
  • Business Wire.5天前
  • AVEO +1.5% as CEO adds to stake
  • seekingalpha.11/26 18:36
  • AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference
  • Business Wire.11/26 12:00

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

AVEO 简况

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
展开

Webull提供AVEO Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。